Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Novocure

< Previous 1 2 3 4 Next >
Novocure Reports Third Quarter 2025 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Present New Research for Tumor Treating Fields (TTFields) Therapy at European Association of Neuro-Oncology (EANO) Meeting and the European Society for Medical Oncology (ESMO) Congress
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report Third Quarter 2025 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting
From Novocure
Via Business Wire
Tickers NVCR
Novocure’s Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Upcoming Investor Events
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
From Novocure
Via Business Wire
Tickers NVCR
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports Second Quarter 2025 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report Second Quarter 2025 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Upcoming Investor Events
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports First Quarter 2025 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Present Results from the Phase 3 PANOVA-3 Clinical Trial of its Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer as a Late-Breaking Oral Presentation at the 2025 ASCO Annual Meeting
From Novocure
Via Business Wire
Tickers NVCR
Novocure’s Optune Lua® Receives CE Mark Approval for the Treatment of Metastatic Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report First Quarter 2025 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in Leerink Partners 2025 Global Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Preliminary Full Year and Fourth Quarter 2024 Performance and Provides Company Update
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in 43rd Annual J.P. Morgan Healthcare Conference
From Novocure
Via Business Wire
Tickers NVCR
Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Participate in Upcoming Investor Conferences
From Novocure
Via Business Wire
Tickers NVCR
Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma
From Novocure
Via Business Wire
Tickers NVCR
FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma
From Novocure
Via Business Wire
Tickers NVCR
Novocure Appoints Christoph Brackmann as Chief Financial Officer
From Novocure
Via Business Wire
Tickers NVCR
Novocure Reports Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Report Third Quarter 2024 Financial Results
From Novocure
Via Business Wire
Tickers NVCR
Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
From Novocure
Via Business Wire
Tickers NVCR
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.